Skip to main content
AKTS
NASDAQ Life Sciences

Aktis Q3 Loss Widens to $29.9M; $492.9M Cash Funds Plan Into 2029

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$17.04
Mkt Cap
$947.756M
52W Low
$13.96
52W High
$34.19
52W Position info
22% above low
Off High info
50% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

AKTS sits 22% above its 52-week low of $13.96.

Summary

Aktis reported a wider Q3 loss of $29.9M on higher trial spending, yet $492.9M in cash funds operations into 2029. The company also started a third Phase 1b trial and began in-house manufacturing, with first AKY-1189 data expected in Q1 2027.


Key Events · Earnings and Guidance · AKTS

  • Q3 Loss Widens on Trial Spending

    Net loss was $29.9M versus $15.5M a year earlier, as R&D rose to $32.1M from $16.5M on advancing AKY-1189 and AKY-2519 trials.

  • Cash Runway Into 2029

    Cash, cash equivalents and marketable securities totaled $492.9M at September 30, 2026, up from $226.8M at year-end 2025 after the January IPO, funding the operating plan into 2029.

  • Third Phase 1b Trial Started

    BActinium-2 evaluating AKY-2519 in NSCLC and other B7-H3 expressing tumors began, alongside first backfill cohorts in NECTINIUM-2 and BActinium-1.

  • In-House GMP Manufacturing Begins

    Aktis began manufacturing drug product at its 17 Drydock facility and expects to supply clinical trials from it in the first half of 2027.


Analysis · AKTS · Life Sciences

The balance sheet is the real story here: $492.9M in cash and securities funds operations into 2029, so there is no near-term financing need. The quarter's loss widened to $29.9M from $15.5M a year ago as R&D spending nearly doubled to $32.1M on three active Phase 1b trials. Clinical cadence also advanced — a third Phase 1b trial (BActinium-2 in lung cancer) started, backfill cohorts opened in the other two, and in-house GMP manufacturing began, with preliminary AKY-1189 data expected in Q1 2027. For a clinical-stage company, that combination of runway and pipeline execution is what drives the thesis.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AKTS was trading at $17.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $947.8M. The 52-week trading range was $13.96 to $34.19. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AKTS - Latest Insights

AKTS
Oct 01, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $19.30
Real-time Price: $17.04 info
Change: -$2.26 (-12%) info
Market Cap: $947.756M info
AKTS
Jul 10, 2026, 6:11 AM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $28.50
Real-time Price: $17.04 info
Change: -$11.46 (-40%) info
Market Cap: $947.756M info
AKTS
May 21, 2026, 5:21 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $19.12
Real-time Price: $17.04 info
Change: -$2.08 (-11%) info
Market Cap: $947.756M info
AKTS
May 11, 2026, 4:06 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $18.27
Real-time Price: $17.04 info
Change: -$1.23 (-7%) info
Market Cap: $947.756M info
AKTS
May 11, 2026, 4:04 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $18.27
Real-time Price: $17.04 info
Change: -$1.23 (-7%) info
Market Cap: $947.756M info